Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9232004 | 0.87 | PNP (0.44) | PNPHPRT1MEN1KMT2AMAPK1 | |
| SCHEMBL456162 | 0.85 | MAPK1 (0.44) | PNPHPRT1MEN1KMT2AMAPK1 | |
| SCHEMBL6046932 | 0.84 | PNP (0.42) | PNPHPRT1MEN1KMT2AMAPK1 | |
| SCHEMBL7524395 | 0.75 | PNP (0.50) | PNPDHFR | |
| SCHEMBL4813936 | 0.69 | PNP (0.70) | PNPMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL7200361 | 0.69 | PNP (0.46) | PNPHPRT1MEN1KMT2AHBB | |
| SCHEMBL8344972 | 0.69 | PNP (0.60) | PNPDHFRHPRT1 | |
| SCHEMBL8165318 | 0.68 | PNP (0.70) | PNPDHFRMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8341140 | 0.68 | PNP (0.59) | PNPDHFRHPRT1MAPK1HBB | |
| SCHEMBL8344233 | 0.67 | PNP (0.65) | PNPDHFRHPRT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | disclosed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | PNP 4582/4885DHFR 4423/4885HPRT1 3808/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | PNP 4582/4885DHFR 4423/4885HPRT1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.